Biotech IPO 2025 Biotech IPOs Surge Through August 2025: Hengrui Leads Asia, U.S. Market Selective Hengrui’s $1.27B HKEX IPO anchors a global biotech rebound through August 2025, with Caris, Heartflow, and Anthem also showing strong YTD debuts.